314
Views
0
CrossRef citations to date
0
Altmetric
Editor's Corner

Letter from the Editor

Dear reader,

In this issue of Human Vaccines & Immunotherapeutics, you will will find 15 articles constituting a Meeting Supplement from last July's DNA Vaccines meeting in San Diego, US, which highlights leading research in the field of DNA vaccines against both infectious diseases and cancer. The Guest Editors Kenneth Ugen (University of South Florida Morsani College of Medicine, Associate Editor of HV&I) and David Weiner (University of Pennsylvania School of Medicine, Editorial Board of HV&I) introduce all articles in their Editorial (Ugen, p 1887).

In addition to this special section, we are happy to present three Immunotherapy articles: a review on a possible role inflammatory processes might play in epilepsy (Martin, p 2021), a preclinical study of the immunogenicity of an aluminum-adjuvanted anti-VEGF cancer vaccine (Pérez Sanchez, p 2030), and a report on a novel synthetic TLR2 agonist that promotes cross-presentation by APCs in mouse and human (Santone, p 2038).

The Hepatitis section contains an evaluation of 24 years of the universal infant Hepatitis B vaccination program in Hangzhou, China (Du, p 2051), an analysis of practice effectiveness of mother-to-child transmission prevention in three Chinese provinces (Wang, p 2061), and a report on the ability of HB immunoglobulin in the placenta to protect the fetus from infection (Liu, p 2068).

Two articles on Influenza introduce technical guidelines for the application of seasonal influenza vaccine in China (Feng, p 2077), and a comparison of adjuvanted and non-adjuvanted vaccination in children (Vesikari, p 2102). Finally, we present research on epidemiology of herpes zoster among Chinese adults (Zhu, p 2113).

Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!

Sincerely,

Ronald Ellis, PhD

Editor-in-Chief

Adam Weiss

Acquisitions Editor

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.